Zeria Pharmaceutical Co., Ltd. Announces Consolidated Earnings Guidance for the Six Months and Fiscal Year Ending March 31, 2023
August 04, 2022 at 03:00 am
Share
Zeria Pharmaceutical Co., Ltd. announced consolidated earnings guidance for the six months and fiscal year ending March 31, 2023. For the six months, the company expects sales of JPY 33,000 million, Operating income of JPY 3,500 million, Profit attributable to owners of parent of JPY 2,800 million and net income per share of JPY 63.30.
For the year, the company expects sales of JPY 66,000 million, Operating income of JPY 7,000 million, Profit attributable to owners of parent of JPY 5,600 million and net income per share of JPY 126.72.
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
ZERIA PHARMACEUTICAL CO., LTD. 
